keyword
MENU ▼
Read by QxMD icon Read
search

Hiv hcv coinfection

keyword
https://www.readbyqxmd.com/read/29027728/hepatitis-in-aids-patients
#1
REVIEW
Muhammad Imran Qadir
The individuals with HIV infection are more susceptible to develop coinfections with infectious pathogens such as HCV and HBV. The routes of transmission of these pathogens are the same including sexual contact, injection drug use, or at birth from mother to an infant. The main reason of morbidity and mortality in HIV infected individuals is a liver disease in the context of antiretroviral therapy, and coinfection such as HCV and HBV complicates this condition. Nucleos(t)ide analogues are used for HBV infection management, and treatment of HCV infection is done by PegIFN and ribavirin combination and protease inhibitors...
October 13, 2017: Reviews in Medical Virology
https://www.readbyqxmd.com/read/29020338/is-moderate-alcohol-consumption-safe-for-hiv-hepatitis-c-virus-coinfected-women
#2
Vincent Lo Re
No abstract text is available yet for this article.
August 16, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29020184/risk-of-acute-liver-injury-after-statin-initiation-by-human-immunodeficiency-virus-and-chronic-hepatitis-c-virus-infection-status
#3
Dana D Byrne, Janet P Tate, Kimberly A Forde, Joseph K Lim, Matthew Bidwell Goetz, David Rimland, Maria C Rodriguez-Barradas, Adeel A Butt, Cynthia L Gibert, Sheldon T Brown, Roger Bedimo, Matthew S Freiberg, Amy C Justice, Jay R Kostman, Jason A Roy, Vincent Lo Re
Background: Patients with human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescribed statins as treatment for metabolic/cardiovascular disease, but it remains unclear if the risk of acute liver injury (ALI) is increased for statin initiators compared to nonusers in groups classified by HIV/HCV status. Methods: We conducted a cohort study to compare rates of ALI in statin initiators vs nonusers among 7686 HIV/HCV-coinfected, 8155 HCV-monoinfected, 17739 HIV-monoinfected, and 36604 uninfected persons in the Veterans Aging Cohort Study (2000-2012)...
August 16, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29018269/adar1-polymorphisms-are-related-to-severity-of-liver-fibrosis-in-hiv-hcv-coinfected-patients
#4
Luz M Medrano, Juan Berenguer, María A Jiménez-Sousa, Teresa Aldámiz-Echevarria, Francisco Tejerina, Cristina Diez, Lorena Vigón, Amanda Fernández-Rodríguez, Salvador Resino
The adenosine deaminase acting on RNA (ADAR1) gene is an interferon-stimulated gene involved in liver injury protection. Our aim was to analyze the association of polymorphisms within this gene with the severity of liver disease in European HIV/HCV-coinfected patients. We performed a cross-sectional study in 220 patients that underwent a liver biopsy. Five SNPs in the ADAR1 gene (rs1127326, rs1127317, rs1127314, rs1127313, rs2229857) were genotyped by GoldenGate assay. The outcome variables were fibrosis stage and necroinflammatory activity grade by METAVIR-score, aspartate aminotransferase to platelet ratio index (APRI), FIB-4 index, and fibrosis progression rate (FPR)...
October 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28990680/baseline-ns5a-resistance-associated-substitutions-may-impair-daa-response-in-real-world-hepatitis-c-patients
#5
Itziar Carrasco, Ana Arias, Laura Benítez-Gutiérrez, Gema Lledó, Silvia Requena, Miriam Cuesta, Valentín Cuervas-Mons, Carmen de Mendoza
BACKGROUND: Oral DAA have demonstrated high efficacy as treatment of hepatitis C. However, the presence of resistance-associated substitutions (RAS) at baseline has occasionally been associated with impaired treatment response. Herein, we examined the impact of baseline RAS at the HCV NS5A gene region on treatment response in a real-life setting. METHODS: All hepatitis C patients treated with DAA including NS5A inhibitors at our institution were retrospectively examined...
October 9, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28971607/lack-of-clinically-important-pk-interaction-between-coformulated-ledipasvir-sofosbuvir-and-rilpivirine-emtricitabine-tenofovir-alafenamide
#6
Joseph M Custodio, Susan K Chuck, Hoa Chu, Huyen Cao, Grace Ma, John Flaherty, John Ling, Brian P Kearney
The drug-drug interaction (DDI) potential between the fixed-dose combinations of ledipasvir/sofosbuvir 90/400 mg for hepatitis C virus and emtricitabine/rilpivirine/tenofovir alafenamide (TAF) 200/25/25 mg for HIV was evaluated in a randomized, open-label, single-center, multiple-dose, 3-way, 6-sequence, crossover Phase 1 study in 42 healthy subjects. Emtricitabine/rilpivirine/TAF had no relevant effect on the pharmacokinetic parameters of maximum concentration [Cmax ] and area under the concentration versus time curve over the dosing interval [AUCtau ] for ledipasvir, sofosbuvir, and the metabolites GS-566500 and GS-331007...
October 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28965214/serological-and-molecular-markers-of-hepatitis-e-virus-infection-in-hiv-infected-patients-in-brazil
#7
A C Ferreira, Michele Soares Gomes-Gouvêa, G Lisboa-Neto, M C J Mendes-Correa, C M Picone, N A Salles, A Mendrone-Junior, F J Carrilho, J R R Pinho
In Brazil, the circulation of hepatitis E virus (HEV) has been demonstrated in distinct groups of individuals and some animals, but its prevalence among individuals with human immunodeficiency virus (HIV) infection is unknown. This study aimed to assess the frequency of serological and molecular HEV markers in individuals infected with HIV from São Paulo, Brazil. Serum and plasma samples of 354 HIV-infected patients collected between 2007 and 2013 were included. All samples were tested for anti-HEV IgG and IgM antibodies and HEV RNA...
September 30, 2017: Archives of Virology
https://www.readbyqxmd.com/read/28960371/acquired-hemophilia-a-resolution-in-an-hcv-hiv-coinfected-patient-with-cure-of-hepatitis-c-by-direct-antiviral-agents
#8
Laetitia Mauge, Juliette Pavie, Dominique Batisse, Luc Darnige
No abstract text is available yet for this article.
September 28, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28954067/profile-of-hiv-subtypes-in-hiv-hbv-and-hiv-hcv-coinfected-patients-in-southern-brazil
#9
Valéria Miranda Avanzi, Bianca Arão Vicente, Nayara Carvalho Polido Beloto, Monica Maria Gomes-da-Silva, Clea Elisa Lopes Ribeiro, Felipe Francisco Tuon, Luine Rosele Renaud Vidal, Meri Bordignon Nogueira, Sonia Mara Raboni
INTRODUCTION: HIV and viral hepatitis infections are major causes of chronic disease worldwide and have some similarities with regard to routes of transmission, epidemiology, front barriers faced during access of treatment, and strategies for a global public health response. The objective was to describe the HIV-1 subtypes, viral tropism and single-nucleotide polymorphisms (SNPs) of interleukin 28B (IL28B) from a case series of HIV/viral hepatitis coinfected patients from southern Brazil...
July 2017: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/28951779/cd4-t-cells-and-natural-killer-cells-biomarkers-for-hepatic-fibrosis-in-human-immunodeficiency-virus-hepatitis-c-virus-coinfected-patients
#10
Natalia Laufer, Diego Ojeda, María Laura Polo, Ana Martinez, Héctor Pérez, Gabriela Turk, Pedro Cahn, Norberto Walter Zwirner, Jorge Quarleri
AIM: To characterize peripheral blood natural killer (NK) cells phenotypes by flow cytometry as potential biomarker of liver fibrosis in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients. METHODS: Peripheral mononuclear cells from 24 HIV/HCV (HBV negative) coinfected and 5 HIV/HCV/HBV seronegative individuals were evaluated. HIV/HCV coinfected patients were divided in to groups: G1, patients with METAVIR F0-F2 and G2, patients with METAVIR F3-F4...
September 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28951598/prevalence-and-predictors-of-liver-disease-in-hiv-infected-children-and-adolescents
#11
Maria Pokorska-Śpiewak, Aleksandra Stańska-Perka, Jolanta Popielska, Agnieszka Ołdakowska, Urszula Coupland, Konrad Zawadka, Małgorzata Szczepańska-Putz, Magdalena Marczyńska
Liver disease in HIV-infected patients may result from the infection itself, antiretroviral treatment or comorbidities. In this study, we analysed liver disease in 79 HIV-infected children and adolescents aged 14.0 ± 5.1 years. All the patients were receiving combination antiretroviral therapy (cART), with a mean duration of 11.5 ± 4.7 years. Six patients (8%) had detectable HIV viral load, and 8/79 (10%) of the participants were coinfected with hepatitis B or C virus (HCV, 6/8 or HBV, 2/8). Liver disease was defined as an elevation of any of the following parameters: alanine or aspartate aminotransferase (ALT and AST), total bilirubin, and gamma glutamyl transferase (GGTP)...
September 26, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28948181/liver-cirrhosis-as-a-risk-factor-for-direct-acting-antiviral-therapy-failure-in-real-life-hepatitis-c-virus-human-immunodeficiency-virus-coinfection
#12
Christoph Boesecke, Patrick Ingiliz, Florian Berger, Thomas Lutz, Knud Schewe, Julian Schulze Zur Wiesch, Axel Baumgarten, Stefan Christensen, Jürgen K Rockstroh, Stefan Mauss
Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are less likely to achieve viral eradication.
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28948180/safety-and-efficacy-of-ombitasvir-paritaprevir-with-ritonavir-%C3%A2-dasabuvir-with-or-without-ribavirin-in-patients-with-human-immunodeficiency-virus-1-and-hepatitis-c-virus-genotype-1-or-genotype-4-coinfection-turquoise-i-part-2
#13
Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, David Wyles, Anne F Luetkemeyer, Adriano Lazzarin, Ruth Soto-Malave, Mark R Nelson, Sanjay R Bhagani, Hartwig H F Klinker, Giuliano Rizzardini, Pierre-Marie Girard, Cristina Tural, Nancy S Shulman, Niloufar Mobashery, Yiran B Hu, Linda M Fredrick, Tami Pilot-Matias, Roger Trinh, Edward Gane
BACKGROUND: Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for HCV genotype 1, and OBV/PTV/r + RBV for HCV genotype 4, in human immunodeficiency virus (HIV)-1 coinfected patients with or without compensated cirrhosis. METHODS: TURQUOISE-I, Part 2 is a phase 3 multicenter study...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28947524/elbasvir-grazoprevir-a-new-direct-acting-antiviral-combination-for-hepatitis-c
#14
REVIEW
Lamis R Karaoui, Hanine Mansour, Elias B Chahine
PURPOSE: The chemistry, pharmacology, pharmacodynamics, pharmacokinetics, efficacy, safety, dosage, administration, and role of elbasvir-grazoprevir in the treatment of hepatitis C virus (HCV) infection are reviewed. SUMMARY: Elbasvir-grazoprevir was recently approved by the Food and Drug Administration for the treatment of chronic HCV genotype 1 or 4 infections with or without ribavirin in patients with or without compensated cirrhosis. Elbasvir exhibits antiviral activity against HCV genotypes 1a, 1b, 2a, 3a, and 4a...
October 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28947403/hepatitis%C3%A2-b-c-and-e-infection-among-hiv-infected-patients-in-franceville-gabon-retrospective-cross-sectional-study
#15
B Bivigou-Mboumba, F Rouet, A Mouinga-Ondeme, L Deleplancque, J Sica, A Ndjoyi-Mbiguino, R Njouom, S François-Souquière
Access to antiretrovirals has increased the life expectancy of patients living with HIV. However, HIV-viral hepatitis coinfections in countries endemic for these infections make management more difficult. To determine the extent of these coinfections in Gabon, we investigated markers of hepatitis B, C, and E viruses in 762 adults infected with HIV-1 by ELISA. We used real-time PCR to quantify plasma HBV DNA (HBV VL) and amplified HCV and HEV RNA by nested RT-PCR and PCR.The seroprevalence of chronic hepatitis B infection was 9...
August 1, 2017: Médecine et Santé Tropicales
https://www.readbyqxmd.com/read/28931691/vertical-transmission-of-hepatitis-c-virus-variable-transmission-bottleneck-and-evidence-of-mid-gestation-in-utero-infection
#16
Sébastien Fauteux-Daniel, Ariane Larouche, Virginie Calderon, Jonathan Boulais, Chanel Béland, Doris G Ransy, Marc Boucher, Valérie Lamarre, Normand Lapointe, Isabelle Boucoiran, Armelle Le Campion, Hugo Soudeyns
Hepatitis C virus (HCV) can be transmitted from mother to child during pregnancy and childbirth. However, the timing and precise biologic mechanisms that are involved in this process are incompletely understood, as are the determinants that influence transmission of particular HCV variants. Here we report results of a longitudinal assessment of HCV quasispecies diversity and composition in 5 cases of vertical HCV transmission, including 3 women coinfected with HIV-1. The population structure of HCV variant spectra based on E2 envelope gene sequences (nucleotide positions 1491-1787), including hypervariable regions 1 and 2, was characterized using next-generation sequencing and median joining network analysis...
September 20, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28926562/generics-for-the-treatment-of-hepatitis-c-in-monoinfected-and-hiv-coinfected-patients-pros-and-cons
#17
Dario Cattaneo, Alessandro Fossati, Chiara Resnati, Massimo Galli, Cristina Gervasoni
The treatment of hepatitis C virus in monoinfected and HIV-coinfected patients has greatly changed over recent years as a result of the introduction of direct-acting antiviral agents (DAAs), which have revolutionized clinical outcomes and led to sustained virological response rates above 90-95%. The discovery of new molecules and the subsequent competition between pharmaceutical companies, together with the negotiated price policies pursued by many national health systems, have led to a gradual reduction in the cost of DAAs, and expand their use to an increasing number of patients, including those with mild liver damage...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28926561/mechanisms-of-accelerated-liver-fibrosis-in-hiv-hcv-coinfection
#18
Theofilos Chrysanthidis, Georgia Loli, Simeon Metallidis, Georgios Germanidis
Although there is evidence that HCV progresses rapidly in HIV/HCV coinfected patients in comparison with HCV monoinfected, the HIV-, HCV- and host/genetic-related factors, as well as the exact mechanisms implicated in this process are not fully elucidated. Furthermore, cure of HCV in those coinfected seems possible with the new antiviral drugs, but high cost as well as insufficient identification, linkage with care and treatment hamper the achievement of this goal. Research on the subject, could reveal an important prognostic marker for the effectiveness of persuasion of patients with HIV/HCV coinfection with a predicted accelerated fibrosis course, in order to facilitate and prioritize, not in terms of guidelines but in the real life situation, their treatment with a medically just framework...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28921677/clinical-profile-of-hepatitis-c-virus-infection-in-a-developing-country-india
#19
Ramit Mahajan, Vandana Midha, Omesh Goyal, Varun Mehta, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Dharmatma Singh, Rishu Bhanot, Ajit Sood
BACKGROUND: The epidemiology and clinical profile of hepatitis C virus (HCV) varies worldwide and data from developing countries is sparse. AIMS: To study the clinical profile of HCV infection in a developing country in South East Asia (India). METHODS: This observational study assessed patient demographics, viral characteristics, risk factors for virus acquisition and disease characteristics in HCV patients diagnosed between January 2004 and December 2015...
September 18, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28902679/brief-report-peripheral-monocyte-macrophage-phenotypes-associated-with-the-evolution-of-cognitive-performance-in-hiv-infected-patients
#20
Massimiliano Fabbiani, Antonio Muscatello, Paolo Perseghin, Marco Bani, Arianna Incontri, Nicola Squillace, Giuseppe Lapadula, Andrea Gori, Alessandra Bandera
BACKGROUND: The contribution of monocyte activation in the development of HIV-associated neurocognitive disorders is not completely understood. This study aimed to explore the predictive value of peripheral monocyte/macrophage (M/M) phenotypes on the evolution of cognitive performance in a population of virologically suppressed HIV-infected patients. SETTING: Prospective, observational, longitudinal study. METHODS: HIV-1-infected patients with HIV-RNA <50copies/mL for >12 months underwent neuropsychological examination at baseline and after 1 year...
October 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
keyword
keyword
98545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"